For citations:
Gavrilova D.A., Besova N.S., Obarevich E.S., Makiev G.G., Rays A.B., Artamonova E.V., Stylidi I.S., Tryakin A.A. Interim results of a prospective randomised single-centre phase III study comparing mFOLFIRINOX and mFOLFOX6 regimens in the first-line treatment of HER2-negative gastric adenocarcinoma. Medical alphabet. 2024;(17):42-48. (In Russ.) https://doi.org/10.33667/2078-5631-2024-17-42-48
Email this article 